| NCT02471560 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2015-11-06 | PHASE4 |
| NCT02461069 | University Hospital Muenster|Biogen | Multiple Sclerosis, Relapsing-Remitting | 2015-05-06 | PHASE4 |
| NCT02644083 | Oregon Health and Science University|Biogen | Multiple Sclerosis | 2016-02 | |
| NCT04292080 | Assistance Publique - H?pitaux de Paris | Age-related Macular Degeneration (AMD) | 2022-02-07 | PHASE2 |
| NCT01911767 | Biogen | Multiple Sclerosis|Exposure During Pregnancy | 2013-10-30 | |
| NCT01156311 | Biogen | Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis | 2010-06 | PHASE2 |
| NCT02981082 | Robert Lafyatis|Biogen | Systemic Sclerosis|Pulmonary; Hypertension | 2016-12 | PHASE1 |
| NCT04890379 | Xuanwu Hospital, Beijing | Intracerebral Hemorrhage | 2021-06-01 | PHASE2 |
| NCT02519413 | Biogen | Multiple Sclerosis | 2015-07 | |
| NCT02969304 | Biogen | Multiple Sclerosis | 2016-12-30 | |
| NCT02419638 | Brigham and Women´s Hospital|EMD Serono | Multiple Sclerosis | 2015-05 | |
| NCT02047097 | Biogen | Multiple Sclerosis | 2013-11-19 | |
| NCT02283853 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-08-28 | PHASE3 |
| NCT04890353 | Xuanwu Hospital, Beijing | Acute Ischemic Stroke | 2021-12-01 | PHASE1|PHASE2 |
| NCT02159573 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-07 | |
| NCT02746744 | Anders Svenningsson | Multiple Sclerosis, Relapsing-Remitting | 2016-05 | PHASE3 |
| NCT06705608 | University of British Columbia | Multiple Sclerosis|Skin Cancer|Skin Cancer Melanoma|Skin Cancers - Basal Cell Carcinoma|Skin Cancer, Squamous Cell|Multiple Sclerosis (MS) - Relapsing-remitting | 2003-01-01 | |
| NCT02686684 | University at Buffalo | Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging | 2015-11 | |
| NCT02097849 | Biogen | Relapsing Forms of Multiple Sclerosis | 2015-02-28 | PHASE2 |
| NCT03870763 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2019-03-19 | PHASE3 |
| NCT00835770 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2009-02-03 | PHASE3 |
| NCT04221191 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2019-08-19 | |
| NCT07548996 | Nanjing Medical University | Type 1 Diabetes Mellitus | 2026-04-27 | PHASE2|PHASE3 |
| NCT01838668 | Biogen | Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis | 2013-03-28 | PHASE3 |
| NCT01915901 | Biogen | Healthy | 2013-08 | PHASE1 |
| NCT01903291 | Biogen | Relapsing Forms of Multiple Sclerosis | 2013-08 | |
| NCT02546440 | Universit?tsmedizin Mannheim|Klinikum Minden|Klinikum Krefeld|Wuerzburg University Hospital|KKS Netzwerk|Klinikum Ludwigshafen|University of Kiel | Cutaneous T Cell Lymphoma | 2015-09 | PHASE2 |
| NCT02410200 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2015-09-30 | PHASE2 |
| NCT02343159 | Biogen | Multiple Sclerosis | 2015-02-28 | PHASE4 |
| NCT03092544 | Multiple Sclerosis Center of Northeastern New York|Icahn School of Medicine at Mount Sinai|Biogen | Multiple Sclerosis | 2015-02 | PHASE4 |
| NCT06850597 | Medical University of Lodz | MCI|MCI-AD, Early Stage Alzheimer´s Disease|Alzheimer´s Disease | 2024-10-28 | PHASE2 |
| NCT01281111 | Biogen | Healthy | 2011-02-01 | PHASE1 |
| NCT02430532 | Biogen | Multiple Sclerosis, Secondary Progressive | 2015-05 | PHASE3 |
| NCT03345940 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova | Relapsing Remitting Multiple Sclerosis | 2017-04-30 | PHASE4 |
| NCT05658497 | Biogen | Multiple Sclerosis | 2023-10-27 | |
| NCT04756687 | Biogen | Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting | 2021-03-10 | |
| NCT04468165 | Hikma Pharmaceuticals LLC | Relapsing Remitting Multiple Sclerosis | 2021-02-23 | |
| NCT01930708 | Biogen | Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis | 2013-10-31 | PHASE4 |
| NCT05762003 | IMPULS Endowment Fund | Multiple Sclerosis | 2019-01-01 | |
| NCT05959759 | Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Chao Yang Hospital|Henan Provincial People´s Hospital | Intracranial Aneurysm|Aneurysm, Brain|Inflammation Vascular | 2023-07-31 | PHASE4 |
| NCT03093324 | Biogen|Alkermes, Inc. | Relapsing Remitting Multiple Sclerosis | 2017-03-15 | PHASE3 |
| NCT02125604 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-06 | PHASE4 |
| NCT04263610 | Almirall, S.A. | Plaque Psoriasis | 2019-09-04 | PHASE4 |
| NCT01815723 | Forward-Pharma GmbH | Plaque Psoriasis | 2016-06 | PHASE3 |
| NCT05658484 | Biogen | Multiple Sclerosis | 2023-06-09 | PHASE4 |
| NCT02555215 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2016-02-22 | PHASE3 |
| NCT05811949 | IRCCS Centro Neurolesi Bonino Pulejo | Multiple Sclerosis | 2021-02-24 | |
| NCT02428218 | Biogen | Relapsing-Remitting Multiple Sclerosis|Relapsing Forms of Multiple Sclerosis | 2016-05 | PHASE3 |
| NCT02410278 | Biogen | Multiple Sclerosis | 2015-03-12 | PHASE4 |
| NCT04891497 | Xuanwu Hospital, Beijing | Acute Ischemic Stroke | 2021-06-01 | PHASE2 |
| NCT01924832 | Biogen | Healthy | 2013-08 | PHASE1 |
| NCT05344469 | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 2022-05-10 | |
| NCT04890366 | Xuanwu Hospital, Beijing | Acute Ischemic Stroke | 2021-12-01 | PHASE1|PHASE2 |
| NCT05767736 | Biogen | Multiple Sclerosis | 2024-06-08 | |
| NCT07483632 | Biogen | Relapsing Forms of Multiple Sclerosis | 2026-11-16 | PHASE3 |
| NCT04676204 | Monash University | Multiple Sclerosis|Adherence, Medication | 2020-09-25 | |
| NCT06513533 | Pujol, Aurora, M.D.|Instituto de Salud Carlos III|Spanish Clinical Research Network - SCReN|Institut d´Investigació Biomèdica de Bellvitge | Adrenomyeloneuropathy Without Cerebral Involvement | 2024-04-23 | PHASE2|PHASE3 |
| NCT02736279 | Virginia Simnad|Biogen | Multiple Sclerosis | 2015-05 | |
| NCT03101735 | Genesis Pharma CNS & Specialty | RRMS | 2016-09-23 | |
| NCT02090413 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2014-05 | PHASE4 |
| NCT02323269 | Biogen | Multiple Sclerosis, Relapsing-Remitting|Relapsing-Remitting Multiple Sclerosis | 2015-05 | |
| NCT02675413 | Washington University School of Medicine|Biogen | Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting | 2016-04 | PHASE4 |
| NCT02171208 | Biogen | Healthy | 2014-06 | PHASE1 |
| NCT07138833 | Qilu Pharmaceutical (Hainan) Co., Ltd. | Relapsing Multiple Sclerosis | 2025-09 | PHASE4 |
| NCT02959658 | Rigshospitalet, Denmark|Biogen | Primary Progressive Multiple Sclerosis | 2016-12 | PHASE2 |
| NCT02472938 | Biogen|GB Pharma Services & Consulting s.r.l. | Relapsing Remitting Multiple Sclerosis | 2015-07 | PHASE4 |
| NCT02784834 | Michael Choi|The Leukemia and Lymphoma Society | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma | 2016-06 | PHASE1 |
| NCT02901106 | Fondation Ophtalmologique Adolphe de Rothschild | Multiple Sclerosis, Relapsing-Remitting | 2017-05-23 | PHASE4 |
| NCT02090348 | Biogen | Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis | 2015-06 | PHASE4 |
| NCT02525874 | Biogen | Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis | 2015-08-11 | PHASE3 |
| NCT07258394 | Nanjing Medical University|The First Affiliated Hospital with Nanjing Medical University|Qilu Pharmaceutical (Hainan) Co., Ltd. | Type 1 Diabetes | 2026-01-27 | PHASE3 |
| NCT04570670 | Banner Life Sciences LLC | Relapsing Remitting Multiple Sclerosis | 2017-01-06 | PHASE1 |
| NCT02428231 | Biogen | Multiple Sclerosis | 2015-04 | PHASE3 |
| NCT01568112 | Biogen | Healthy | 2012-04 | PHASE3 |
| NCT03526224 | University at Buffalo | Tecfidera|Teriflunomide | 2018-06-14 | |
| NCT04381936 | University of Oxford|UK Research and Innovation|National Institute for Health Research, United Kingdom|Wellcome Trust|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Health Data Research UK|Medical Research Council Population Health Research Unit|NIHR Health Protection Research Unit in Emerging and Zoonotic Infections|Flu Lab | Pneumonia | 2020-03-19 | PHASE3 |
| NCT02579681 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 2014-04-30 | PHASE3 |
| NCT00420212 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2007-01 | PHASE3 |
| NCT02683863 | Multiple Sclerosis Center of Northeastern New York|Biogen | Multiple Sclerosis | 2015-08 | PHASE4 |
| NCT01873417 | Biogen | Relapsing Forms of Multiple Sclerosis | 2013-05 | PHASE4 |
| NCT00168701 | Biogen | Multiple Sclerosis | 2004-10-01 | PHASE2 |
| NCT00451451 | Biogen | Relapsing-Remitting Multiple Sclerosis | 2007-06 | PHASE3 |
| NCT00837785 | Biogen | Relapsing Remitting Multiple Sclerosis | 2009-02-28 | PHASE1 |
| NCT01069913 | Biogen | Healthy | 2009-10 | PHASE1 |
| NCT01453426 | Biogen | Healthy | 2012-01 | PHASE1 |
| NCT00810836 | Biogen | Rheumatoid Arthritis | 2008-12 | PHASE2 |
| NCT02823951 | IMS HEALTH GmbH & Co. OHG|EMD Serono | Relapsing-remitting Multiple Sclerosis | 2016-02 | |
| NCT02739542 | University of Texas Southwestern Medical Center|Biogen | Multiple Sclerosis (MS) | 2016-03-19 | PHASE4 |
| NCT02975349 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany | Relapsing-remitting Multiple Sclerosis | 2017-03-07 | PHASE2 |
| NCT02218879 | Yale University | Multiple Sclerosis | 2014-08 | |
| NCT04022473 | Banner Life Sciences LLC | Multiple Sclerosis | 2019-07-07 | PHASE1 |